Teva announced the projected launch of ProAir HFA (albuterol sulfate inhalation aerosol) with a dose counter for use in patients >4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB).

Albuterol sulfate, a short-acting β2-agonist, works to relax the smooth muscle of all airways, from the trachea to the terminal bronchioles. ProAir HFA is supplied in an 8.5g canister containing 200 actuations. Each inhalation delivers 108mcg of albuterol sulfate. ProAirHFA is expected to be available later in 2012.

For more information call (888) 838-2872 or visit www.ProAirHFA.com.